Lv31
240 积分 2023-08-25 加入
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
1小时前
待确认
New promises and challenges in the treatment of advanced non-small-cell lung cancer
5小时前
已完结
The present and future of bispecific antibodies for cancer therapy
11个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
1年前
已完结
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
1年前
已完结
Cancer statistics in China and United States, 2022: profiles, trends, and determinants
1年前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1年前
已完结
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
1年前
已完结
Emerging Strategies for the Treatment of Small Cell Lung Cancer
1年前
已完结
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
1年前
已完结
皖公网安备34019202002308
